Ваша корзина пуста
<< все статьи
V.Savinov, Moscow.

235 prostatic cancer patients received immunomodulators against the background of estrogen therapy. In 87.8 % of cases a 5-year survival rate was reached. All patients were subjected to immunologic and hormonal tests. Determined were hemostasis indices and enzimatic markers of prostatic cancer. In addition, 12 patients underwent biopsy of 1 and 4 years. Of them, 6 patients received only estrogens, 6 other patients – estrogens and immunodulators. In all the cases the dynamics of the results of a hystologic investigations was similar: when treating with immunotropic preparations, the histologic structure showed the prevalence of estrogen-resistant forms was registered, or the structure of the tumor remained unchanged.